Novartis sees 2019 growth as it sheds eyecare unit, narrows focus

Swiss drugmaker Novartis sees mid-single-digit sales growth from its core businesses in 2019 as it sheds its Alcon eyecare unit and a U.S. generics pills business to focus on newer high-tech drugs.Read More